Objective To conduct a systematic review of economic models of newer anticoagulants for
stroke prevention in atrial fibrillation (SPAF). Patients and Methods We searched Medline …

Summary Background and Objectives Benefits and/or harms (including costs) of non‐
vitamin K oral anticoagulants (NOAC s) versus warfarin therapy need appreciation in relative …

Introduction: Several comparative real-world effectiveness studies on direct oral
anticoagulants (DOACs) have been conducted, but an overview of the available evidence …

Emerging observational studies using propensity score (PS) methods assessed real-world
comparative effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) versus …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Background This study compares the total medical costs with the use of the new oral
anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban vs. warfarin in the US …

We did a cost-utility analysis for the new oral anticoagulants (NOACs) in the German
population based on the quality-adjusted life years (QALY), total costs, and incremental cost …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

Abstract Background Novel oral anticoagulants (NOACs) expand the treatment options for
patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk–benefit …

OBJECTIVE To summarize the available evidence on the issues in health economics related
to oral anticoagulation for stroke prevention in atrial fibrillation (AF) in the US. DATA …